WallStSmart

Coherent Inc (COHR)vsMKS Instruments Inc (MKSI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Coherent Inc generates 62% more annual revenue ($6.60B vs $4.07B). MKSI leads profitability with a 8.0% profit margin vs 7.1%. COHR appears more attractively valued with a PEG of 0.92. MKSI earns a higher WallStSmart Score of 61/100 (C+).

COHR

Buy

56

out of 100

Grade: C

Growth: 7.3Profit: 5.0Value: 5.0Quality: 7.5
Piotroski: 5/9Altman Z: 1.53

MKSI

Buy

61

out of 100

Grade: C+

Growth: 7.3Profit: 6.5Value: 3.3Quality: 5.0
Piotroski: 4/9Altman Z: 1.24
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COHR.

MKSISignificantly Overvalued (-75.4%)

Margin of Safety

-75.4%

Fair Value

$147.68

Current Price

$301.65

$153.97 premium

UndervaluedFair: $147.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COHR4 strengths · Avg: 8.8/10
EPS GrowthGrowth
73.0%10/10

Earnings expanding 73.0% YoY

Market CapQuality
$77.84B9/10

Large-cap with strong market position

PEG RatioValuation
0.928/10

Growing faster than its price suggests

Revenue GrowthGrowth
20.5%8/10

Revenue surging 20.5% year-over-year

MKSI2 strengths · Avg: 9.0/10
EPS GrowthGrowth
53.2%10/10

Earnings expanding 53.2% YoY

Revenue GrowthGrowth
15.2%8/10

15.2% revenue growth

Areas to Watch

COHR4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.534/10

Distress zone — elevated risk

Return on EquityProfitability
4.4%3/10

ROE of 4.4% — below average capital efficiency

Profit MarginProfitability
7.1%3/10

7.1% margin — thin

P/E RatioValuation
188.6x2/10

Premium valuation, high expectations priced in

MKSI2 concerns · Avg: 2.0/10
P/E RatioValuation
74.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.242/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : COHR

The strongest argument for COHR centers on EPS Growth, Market Cap, PEG Ratio. Revenue growth of 20.5% demonstrates continued momentum. PEG of 0.92 suggests the stock is reasonably priced for its growth.

Bull Case : MKSI

The strongest argument for MKSI centers on EPS Growth, Revenue Growth. Revenue growth of 15.2% demonstrates continued momentum. PEG of 1.32 suggests the stock is reasonably priced for its growth.

Bear Case : COHR

The primary concerns for COHR are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 188.6x leaves little room for execution misses.

Bear Case : MKSI

The primary concerns for MKSI are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.

Key Dynamics to Monitor

COHR carries more volatility with a beta of 2.05 — expect wider price swings.

COHR is growing revenue faster at 20.5% — sustainability is the question.

MKSI generates stronger free cash flow (28M), providing more financial flexibility.

Monitor SCIENTIFIC & TECHNICAL INSTRUMENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MKSI scores higher overall (61/100 vs 56/100) and 15.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coherent Inc

TECHNOLOGY · SCIENTIFIC & TECHNICAL INSTRUMENTS · USA

Coherent, Inc. provides lasers, laser-based technologies, and laser-based system solutions for a variety of scientific, commercial, and industrial research applications. The company is headquartered in Santa Clara, California.

MKS Instruments Inc

TECHNOLOGY · SCIENTIFIC & TECHNICAL INSTRUMENTS · USA

MKS Instruments, Inc. provides instruments, systems, subsystems, and process control solutions that measure, monitor, deliver, analyze, power, and control critical parameters of manufacturing processes globally. The company is headquartered in Andover, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?